Overview

Study of REGN1193 in Patients With Type 2 Diabetes Mellitus

Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of REGN1193 in patients with Type 2 Diabetes Mellitus.
Phase:
Phase 1
Details
Lead Sponsor:
Regeneron Pharmaceuticals